| GHS-Einstufung | This chemical does not meet GHS hazard criteria for 0.5% (1 of 187) of reports.DangerH315 (24.6%): Causes skin irritation [Warning Skin corrosion/irritation]P203, P233, P260, P261, P264, P264+P265, P271, P272, P273, P280, P284, P302+P352, P304+P340, P305+P351+P338, P318, P319, P321, P332+P317, P333+P317, P337+P317, P342+P316, P362+P364, P391, P403, P403+P233, P405, and P501 (click each P-code to see the statement)Aggregated GHS information provided per 187 reports by companies from 31 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies. |
|---|
| Gesundheitsgefahren | SYMPTOMS: Symptoms of exposure to this type of compound include fluid and electrolyte disturbances, pituitary-adrenal suppression, hyperglycemia, increased susceptibility to infection including tuberculosis, myopathy, growth arrest, hypokalemic alkalosis and Cushing's syndrome consisting of "moon-face", "buffalo-hump", striae, acne and hirsuitism. Other symptoms of Cushing's syndrome include enlargement of supraclavicular fat pads, "central obesity" and ecchymoses. Flushing and increased bruising may also occur with this syndrome. Other symptoms of exposure include behavioral disturbances, glycosuria, nervousness, changes in mood or psyche, psychopathies of the manic-depressive or schizophrenic type and suicidal tendencies. Exposure may cause candidiasis, gluconeogenesis, cardiac failure (in extreme cases), spontaneous fractures, increased appetite, delayed wound healing, hyperhidrosis, mental and neurological disturbances, intracranial hypertension and increase in coagulability of the blood. It may also cause peptic ulceration with perforation or hemorrhage, amenorrhea, aseptic necrosis of the bone, muscular weakness, salt and water retention, hypertension, edema, increase in severity of diabetes, pancreatitis, thrombatic episodes and osteoporosis. Other symptoms of exposure to this type of compound include sleeplessness, skin eruptions, depression, euphoria, decrease in pain sensation, weakness, deafness, convulsions, intestinal perforation in ulcerative colitis, hypokalemia, muscle degeneration, rupture of the Achilles tendon, pseudotumor cerebri and cardiac conduction defect. It may cause congestive heart failure, suppression of the immune response mechanism, impairment of glucose tolerance, habituation and unmasking of latent psychiatric disorder. It may also cause potassium loss, loss of muscle mass, vertebral compression fractures, abdominal distention, ulcerative esophagitis, thin and fragile skin, petechiae, erythema, increased sweating, suppressed reactions to skin tests, allergic dermatitis, urticaria, angioneurotic edema, vertigo, headache, menstrual irregularities, secondary adrenocorticol and pituitary unresponsiveness, decreased carbohydrate tolerance, exophthalmos, hypersensitivity, thromboembolism, malaise, weight gain, nausea and intracranial pressure with papilledema. Ascites may occur. Skin exposure to this type of compound may cause loss of skin collagen and subcutaneous atrophy. Other symptoms via this route include burning, secondary infections, itching, irritation, pigmentation, dryness, folliculitis and hypertrichosis. Eye exposure to this type of compound may lead to corneal ulceration, raised intraocular pressure, reduced visual function and cataracts. Glaucoma may also occur. |
|---|
